ALNYLAM PHARMACEUTICALS INC holding history
As of Nov. 6, 2026 (UTC)
| March 31, 2025 | 102,420 | $27,655,448 | 0.30% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | May 15, 2025 |
| June 30, 2025 | 103,003 | $33,588,248 | 0.31% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Aug. 14, 2025 |
| Sept. 30, 2025 | 118,878 | $54,208,368 | 0.49% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Nov. 14, 2025 |
| Dec. 31, 2025 | 48,859 | $19,428,781 | 0.21% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Feb. 17, 2026 |
| March 31, 2026 | 30,604 | $10,125,945 | 0.10% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | May 15, 2026 |
| June 30, 2026 | 29,056 | $8,746,728 | 0.08% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Aug. 14, 2026 |
6 rows · Sort by column; scroll horizontally for more.
No rows match these filters.
Schedule 13G disclosures
No verified related disclosures are included in this freeze.
About reported holdings
13F reports quarter-end securities, excluding cash and shorts. Position changes do not establish trades, motives or returns; portfolio weights use disclosed 13F value.